CD19 and diffuse large B-cell lymphoma: Based on phase 2 or 3 trials, anti-CD19 CAR-T cells have demonstrated efficacy in the treatment of paediatric and adult acute lymphoblastic leukaemia (ALL), adult refractory or relapsed high-grade B cell non-Hodgkin lymphoma (NHL) (for diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma and mantle cell lymphoma), indolent B cell NHL (for follicular lymphoma).